Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

NARecruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Kidney Disease, End-StageEnd-stage Renal DiseaseArteriovenous Fistula
Interventions
DEVICE

EndoAVF Creation

Subjects will have an endoAVF created using the WavelinQ EndoAVF System

Trial Locations (14)

12208

RECRUITING

Albany Medical Center, Albany

13210

TERMINATED

SUNY Upstate Medical University Hospital, Syracuse

16001

RECRUITING

Butler Memorial Hospital, Butler

27609

RECRUITING

NC Nephrology, Raleigh

33156

RECRUITING

Vascular and Interventional Specialists, Miami

33801

RECRUITING

Radiology and Imaging Specialists, Lakeland

38104

RECRUITING

Bluff City Vascular, Memphis

63117

COMPLETED

SSM St. Mary's, St Louis

75226

WITHDRAWN

Baylor Scott & White, Dallas

77030

RECRUITING

Houston Methodist, Houston

WITHDRAWN

University of Texas Health Science Center at Houston, Houston

92037

RECRUITING

California Institute of Renal Research, La Jolla

94117

RECRUITING

San Francisco Vein & Vascular, San Francisco

01655

RECRUITING

UMass Chan School of Medicine, Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

C. R. Bard

INDUSTRY

NCT04634916 - Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System | Biotech Hunter | Biotech Hunter